141 related articles for article (PubMed ID: 37443517)
21. Clinical implications of preoperative thyrotropin serum concentrations in patients who underwent thyroidectomy for nonfunctioning nodule(s).
Kim D; Park JW
J Korean Surg Soc; 2013 Jul; 85(1):15-9. PubMed ID: 23833755
[TBL] [Abstract][Full Text] [Related]
22. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
23. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
Xia Q; Dong S; Bian PD; Wang J; Li CJ
Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
[TBL] [Abstract][Full Text] [Related]
24. Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma.
Vasileiadis I; Boutzios G; Charitoudis G; Koukoulioti E; Karatzas T
Ann Surg Oncol; 2014 Aug; 21(8):2725-32. PubMed ID: 24595799
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological correlation of serum TSH in patients with thyroid nodule.
Mondal HP; Sen S; Sasmal S; Ghosal PK; Mukhopadhyay SK; Mukhopadhyay M
J Indian Med Assoc; 2011 May; 109(5):330, 335, 338. PubMed ID: 22187768
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic characteristics and outcomes of papillary thyroid carcinoma in younger patients.
Lu Y; Jiang L; Chen C; Chen H; Yao Q
Medicine (Baltimore); 2020 Apr; 99(15):e19795. PubMed ID: 32282744
[TBL] [Abstract][Full Text] [Related]
27. High Urinary Iodine, Thyroid Autoantibodies, and Thyroid-Stimulating Hormone for Papillary Thyroid Cancer Risk.
Zhao H; Li H; Huang T
Biol Trace Elem Res; 2018 Aug; 184(2):317-324. PubMed ID: 29164514
[TBL] [Abstract][Full Text] [Related]
28. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.
Bae MR; Nam SH; Roh JL; Choi SH; Nam SY; Kim SY
Endocrine; 2022 Feb; 75(2):487-494. PubMed ID: 34689317
[TBL] [Abstract][Full Text] [Related]
29. Thyroid cancers with benign-looking sonographic features have different lymph node metastatic risk and histologic subtypes according to nodule size.
Shin DY; Lee YK; Kim KJ; Park KH; Hwang S; Park SH; Kim EK; Kwon HJ; Lee EJ
Endocr Pathol; 2014 Dec; 25(4):378-84. PubMed ID: 25182219
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Coexistent Hashimoto's Thyroiditis on Central Compartment Lymph Node Metastasis in Papillary Thyroid Carcinoma.
Liu Y; Lv H; Zhang S; Shi B; Sun Y
Front Endocrinol (Lausanne); 2021; 12():772071. PubMed ID: 34867817
[TBL] [Abstract][Full Text] [Related]
31. High TPOAb Levels (>1300 IU/mL) Indicate Multifocal PTC in Hashimoto's Thyroiditis Patients and Support Total Thyroidectomy.
Dong S; Xia Q; Wu YJ
Otolaryngol Head Neck Surg; 2015 Jul; 153(1):20-6. PubMed ID: 25917667
[TBL] [Abstract][Full Text] [Related]
32. [Association between preoperative serum thyroid-stimulating hormone level and nonfunctioning malignant nodule thyroid disease].
Zeng Q; Liu J; Zhu J; Hu G
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Dec; 28(24):1931-3. PubMed ID: 25895308
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
[No Abstract] [Full Text] [Related]
34. Coexistence of papillary thyroid carcinoma in secondary hyperparathyroidism.
Ma J; Mao Z; Yao Y; Lu Y; Wang H; Yang Y; Yang J; Wang W; Teng L
BMC Surg; 2021 Sep; 21(1):335. PubMed ID: 34488715
[TBL] [Abstract][Full Text] [Related]
35. Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer.
Wu X; Lun Y; Jiang H; Gang Q; Xin S; Duan Z; Zhang J
Endocrine; 2014 Aug; 46(3):554-60. PubMed ID: 24338678
[TBL] [Abstract][Full Text] [Related]
36. Optimal thyrotropin level for low-risk papillary thyroid carcinoma after ultrasound-guided radiofrequency ablation.
Li X; Yan L; Xiao J; Li Y; Zhu Y; Yang Z; Zhang M; Luo Y
Int J Hyperthermia; 2023; 40(1):2160880. PubMed ID: 36599433
[TBL] [Abstract][Full Text] [Related]
37. Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer.
Zhou RY; Li N; Tan HL; Tang N; Chen P; Liu M; Ou-Yang DJ; Qin ZE; Ai L; Wei B; Zhao YX; Chang S; Huang P
Front Endocrinol (Lausanne); 2023; 14():1126592. PubMed ID: 37388210
[TBL] [Abstract][Full Text] [Related]
38. Nodule Size Effect on Diagnostic Performance of Ultrasonography and Computed Tomography for Papillary Thyroid Carcinoma.
Li JW; Chang C; Chen JY; Shi ZT; Chen M
Curr Med Imaging Rev; 2019; 15(5):489-495. PubMed ID: 32008556
[TBL] [Abstract][Full Text] [Related]
39. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
40. Preoperative thyroid-stimulating hormone associated risk of differentiated thyroid cancer in patients with thyroid nodules.
M AE
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):85-91. PubMed ID: 34933729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
